Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03493451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03493451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
April 13, 2018
Completion date
April 21, 2021
Enrollment
77 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

adult nasal type extranodal nk/t-cell lymphoma, alk-negative anaplastic large cell lymphoma, alk-positive anaplastic large cell lymphoma, anaplastic large cell lymphoma, anaplastic large cell lymphoma, alk-negative, anaplastic large cell lymphoma, alk-positive, angioimmunoblastic t-cell lymphoma, angioimmunoblastic t-cell lymphoma recurrent, angioimmunoblastic t-cell lymphoma refractory, cutaneous t-cell lymphoma, extranodal nk t cell lymphoma, extranodal nk t cell lymphoma, nasal, extranodal nk/t-cell lymphoma, extranodal nk/t-cell lymphoma, nasal type, peripheral t cell lymphoma, peripheral t-cell lymphoma nos, peripheral t-cell lymphoma refractory, peripheral t-cell lymphoma, not otherwise specified, ptcl